Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Patients' survival expectations before localized prostate cancer treatment by treatment status.

Mohan R, Beydoun H, Barnes-Ely ML, Lee L, Davis JW, Lance R, Schellhammer P.

J Am Board Fam Med. 2009 May-Jun;22(3):247-56. doi: 10.3122/jabfm.2009.03.080200.

2.

Feasibility of using guidelines to choose treatment for prostate cancer.

Mohan R, Beydoun H, Davis J, Lance R, Schellhammer P.

Can J Urol. 2010 Feb;17(1):4975-84.

PMID:
20156376
3.

Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE.

Kane CJ, Lubeck DP, Knight SJ, Spitalny M, Downs TM, Grossfeld GD, Pasta DJ, Mehta SS, Carroll PR.

Urology. 2003 Dec;62(6):1035-9.

PMID:
14665350
5.

[Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].

Soulié M, Villers A, Richaud P, Prapotnich D, Ruffion A, Grosclaude P.

Prog Urol. 2001 Dec;11(6):1195-204. Review. French.

PMID:
11859652
6.

Patients' Survival Expectations With and Without Their Chosen Treatment for Prostate Cancer.

Xu J, Janisse J, Ruterbusch JJ, Ager J, Liu J, Holmes-Rovner M, Schwartz KL.

Ann Fam Med. 2016 May;14(3):208-14. doi: 10.1370/afm.1926.

7.

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.

Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackmaan S, Moul JW.

J Clin Oncol. 2003 Nov 1;21(21):4001-8.

PMID:
14581423
9.

Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.

Shimizu F, Igarashi A, Fukuda T, Kawachi Y, Minowada S, Ohashi Y, Fujime M.

Jpn J Clin Oncol. 2007 Oct;37(10):763-74. Epub 2007 Oct 22.

PMID:
17956899
10.

Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis.

Lester-Coll NH, Goldhaber SZ, Sher DJ, D'Amico AV.

Cancer. 2013 May 15;119(10):1808-15. doi: 10.1002/cncr.27980. Epub 2013 Feb 7. Erratum in: Cancer. 2013 Jun 15;119(12):2358. Dosage error in article text.

12.

Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).

Schymura MJ, Kahn AR, German RR, Hsieh MC, Cress RD, Finch JL, Fulton JP, Shen T, Stuckart E.

BMC Cancer. 2010 Apr 19;10:152. doi: 10.1186/1471-2407-10-152.

13.

Continued undertreatment of older men with localized prostate cancer.

Schwartz KL, Alibhai SM, Tomlinson G, Naglie G, Krahn MD.

Urology. 2003 Nov;62(5):860-5.

PMID:
14624909
14.

Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.

van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH.

BJU Int. 2009 Jun;103(11):1472-7. doi: 10.1111/j.1464-410X.2008.08281.x. Epub 2009 Jan 19.

15.

Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer.

Godley PA, Schenck AP, Amamoo MA, Schoenbach VJ, Peacock S, Manning M, Symons M, Talcott JA.

J Natl Cancer Inst. 2003 Nov 19;95(22):1702-10.

PMID:
14625261
16.

Counterpoint: prostate cancer life expectancy can not be accurately predicted from currently available tools.

McCloskey SA, Kuettel MR.

J Natl Compr Canc Netw. 2007 Aug;5(7):709-13. Review.

PMID:
17692176
17.

Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinic.

Lintz K, Moynihan C, Steginga S, Norman A, Eeles R, Huddart R, Dearnaley D, Watson M.

Psychooncology. 2003 Dec;12(8):769-83.

PMID:
14681951
18.

Should we treat localized prostate cancer? An opinion.

Menon M, Parulkar BG, Baker S.

Urology. 1995 Nov;46(5):607-16.

PMID:
7495109
19.

Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.

Wilt TJ.

Semin Urol Oncol. 2002 Feb;20(1):10-7. Review.

PMID:
11828353
20.

Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors.

Wever EM, Heijnsdijk EA, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ.

Br J Cancer. 2013 May 28;108(10):1971-7. doi: 10.1038/bjc.2013.198. Epub 2013 May 14.

Supplemental Content

Support Center